Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma
PURPOSE: The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network meta-analysis (NMA) of randomized controlled trials (RCTs) to study the effect of chemotherapy or chemoradiotherapy, with a focus on tumor location and histology subgroups.
PATIENTS AND METHODS: All, published or unpublished, RCTs closed to accrual before December 31, 2015 and having compared at least two of the following strategies were eligible: upfront surgery (S), chemotherapy followed by surgery (CS), and chemoradiotherapy followed by surgery (CRS). All analyses were conducted on IPD obtained from investigators. The primary end point was overall survival (OS). The IPD-NMA was analyzed by a one-step mixed-effect Cox model adjusted for age, sex, tumor location, and histology. The NMA was registered in PROSPERO (CRD42018107158).
RESULTS: IPD were obtained for 26 of 35 RCTs (4,985 of 5,807 patients) corresponding to 12 comparisons for CS-S, 12 for CRS-S, and four for CRS-CS. CS and CRS led to increased OS when compared with S with hazard ratio (HR) = 0.86 (0.75 to 0.99), P = .03 and HR = 0.77 (0.68 to 0.87), P < .001 respectively. The NMA comparison of CRS versus CS for OS gave a HR of 0.90 (0.74 to 1.09), P = .27 (consistency P = .26, heterogeneity P = .0038). For CS versus S, a larger effect on OS was observed for GEJ versus TE tumors (P = .036). For the CRS versus S and CRS versus CS, a larger effect on OS was observed for women (P = .003, .012, respectively).
CONCLUSION: Neoadjuvant chemotherapy and chemoradiotherapy were consistently better than S alone across histology, but with some variation in the magnitude of treatment effect by sex for CRS and tumor location for CS. A strong OS difference between CS and CRS was not identified.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 41(2023), 28 vom: 01. Okt., Seite 4535-4547 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Faron, Matthieu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 29.09.2023 Date Revised 06.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1200/JCO.22.02279 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359678610 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359678610 | ||
| 003 | DE-627 | ||
| 005 | 20240306232336.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.22.02279 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM359678610 | ||
| 035 | |a (NLM)37467395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Faron, Matthieu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2023 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network meta-analysis (NMA) of randomized controlled trials (RCTs) to study the effect of chemotherapy or chemoradiotherapy, with a focus on tumor location and histology subgroups | ||
| 520 | |a PATIENTS AND METHODS: All, published or unpublished, RCTs closed to accrual before December 31, 2015 and having compared at least two of the following strategies were eligible: upfront surgery (S), chemotherapy followed by surgery (CS), and chemoradiotherapy followed by surgery (CRS). All analyses were conducted on IPD obtained from investigators. The primary end point was overall survival (OS). The IPD-NMA was analyzed by a one-step mixed-effect Cox model adjusted for age, sex, tumor location, and histology. The NMA was registered in PROSPERO (CRD42018107158) | ||
| 520 | |a RESULTS: IPD were obtained for 26 of 35 RCTs (4,985 of 5,807 patients) corresponding to 12 comparisons for CS-S, 12 for CRS-S, and four for CRS-CS. CS and CRS led to increased OS when compared with S with hazard ratio (HR) = 0.86 (0.75 to 0.99), P = .03 and HR = 0.77 (0.68 to 0.87), P < .001 respectively. The NMA comparison of CRS versus CS for OS gave a HR of 0.90 (0.74 to 1.09), P = .27 (consistency P = .26, heterogeneity P = .0038). For CS versus S, a larger effect on OS was observed for GEJ versus TE tumors (P = .036). For the CRS versus S and CRS versus CS, a larger effect on OS was observed for women (P = .003, .012, respectively) | ||
| 520 | |a CONCLUSION: Neoadjuvant chemotherapy and chemoradiotherapy were consistently better than S alone across histology, but with some variation in the magnitude of treatment effect by sex for CRS and tumor location for CS. A strong OS difference between CS and CRS was not identified | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Cheugoua-Zanetsie, Maurice |e verfasserin |4 aut | |
| 700 | 1 | |a Tierney, Jayne |e verfasserin |4 aut | |
| 700 | 1 | |a Thirion, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Nankivell, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Winter, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Shapiro, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Vernerey, Dewi |e verfasserin |4 aut | |
| 700 | 1 | |a Smithers, B Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Piessen, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Nilsson, Magnus |e verfasserin |4 aut | |
| 700 | 1 | |a Boonstra, Jurjen |e verfasserin |4 aut | |
| 700 | 1 | |a Ychou, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Law, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Cunningham, David |e verfasserin |4 aut | |
| 700 | 1 | |a de Vathaire, Florent |e verfasserin |4 aut | |
| 700 | 1 | |a Stahl, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Urba, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Valmasoni, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Williaume, Danièle |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Janine |e verfasserin |4 aut | |
| 700 | 1 | |a Lordick, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Tepper, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Roth, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Gebski, Val |e verfasserin |4 aut | |
| 700 | 1 | |a Burmeister, Bryan |e verfasserin |4 aut | |
| 700 | 1 | |a Paoletti, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a van Sandick, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Jianhua |e verfasserin |4 aut | |
| 700 | 1 | |a Pignon, Jean-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Ducreux, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Michiels, Stefan |e verfasserin |4 aut | |
| 700 | 0 | |a MANATEC-02 Collaborative Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 41(2023), 28 vom: 01. Okt., Seite 4535-4547 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:28 |g day:01 |g month:10 |g pages:4535-4547 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.22.02279 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 28 |b 01 |c 10 |h 4535-4547 | ||